Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07184632 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 1, 2026 to Dec 14, 2026v5
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 220 to confirmed 224 · Site details revised at 2 of 2 sitesv4 Show 2 more changesShow less
    • Enrollment target: estimated 220 to confirmed 224
    • Site details revised at 2 of 2 sites
  3. Site details revised at 1 of 2 sitesv3
  4. Trial status: Not Yet Recruiting to Recruiting Site details revised at 2 of 2 sitesv2 Show 1 more changeShow less
    • Site details revised at 2 of 2 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
268 trials monitored
See 15 trials at risk
Obesity
3,560 trials monitored
See 142 trials at risk
This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with overweight or obesity. There are 2 study treatments in this study, participants will get either NNC0662-0419, the treatment being tested or placebo, a treatment that has no active medicine in it. NNC0662-0419 is a new medicine which cannot be pre-scribed by doctors but has previously been tested in humans.
Trial Details
NCT Number NCT07184632
Lead Sponsor Novo Nordisk A/S
Conditions Overweight, Obesity
Enrollment 224 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov